Program
Esomeprazole
Also written as “esomeprazole”, “PN400” and “Esomeprazole (Nexium)”.
Its studies are mostly in Gastroesophageal Reflux · Stomach Ulcer · Heartburn · Esophagitis, Peptic · Gastrointestinal Diseases, led by 15 companies.
Drug pageEsomeprazole: every studyMany companies study it; this page follows only the 122 they lead. All 244 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 920 open or running | phase 4since Sep 12, 2005 | Mar 16, 2004 | none ahead |
| Hanmi Pharmaceuticalits history only | 50 open or running | phase 3since Sep 4, 2019 | Dec 8, 2017 | none ahead |
| Aralez Pharmaceuticalsits history only | 40 open or running | phase 1since Jan 11, 2008 | Jan 11, 2008 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 30 open or running | phase 1since Feb 6, 2018 | Feb 6, 2018 | none ahead |
| Pfizerits history only | 30 open or running | phase 4since Jan 21, 2016 | Feb 25, 2012 | none ahead |
| Takedaits history only | 30 open or running | phase 2since Apr 14, 2016 | Jul 16, 2009 | none ahead |
| Torrent Pharmaceuticalsits history only | 30 open or running | phase 1since Nov 9, 2015 | Nov 9, 2015 | none ahead |
| EMSits history only | 20 open or running | phase 4since Sep 2, 2015 | Sep 2, 2015 | none ahead |
| Elpen Pharmaceuticalits history only | 10 open or running | phase 4since Nov 7, 2016 | Nov 7, 2016 | none ahead |
| Eurofarma Laboratoriosits history only | 10 open or running | phase 3since Oct 31, 2011 | Oct 31, 2011 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Sep 6, 2021 | Sep 6, 2021 | none ahead |
| HALEONits history only | 10 open or running | phase 1since Feb 22, 2022 | Feb 22, 2022 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 4since Apr 20, 2007 | Apr 20, 2007 | none ahead |
| Joincare Pharmaceutical Group Industryits history only | 11 open or running | phase 3since Feb 7, 2025 | Feb 7, 2025 | none ahead |
| SD Biosensorits history only | 10 open or running | phase 4since Jan 19, 2009 | Jan 19, 2009 | none ahead |
Also a collaborator on its studies: IQVIA RDS, Laboratory Corporation of America, Medidata Solutions, Thermo Fisher Scientific, CISCRP, Arvinas Estrogen Receptor, Parexel and Quintiles.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 43 studies since Feb 27, 2007.
- Sep 9, 20102 phase 1 studiesNCT01199328, NCT01210339
- Nov 26, 2010Phase 4 study in HeartburnNCT01249651 · 101 enrolled · China
- May 16, 2011Phase 1 study in Arthritis, JuvenileNCT01358383 · 28 enrolled · United States
- Jun 1, 20112 phase 3 studies in HeartburnNCT01370538, NCT01370525
- Jul 18, 2011Phase 4 study in Gastroesophageal RefluxNCT01397084 · 107 enrolled
- Dec 15, 2011Phase 1 study in Bioequivalence StudyNCT01494402 · 77 enrolled · Japan
- May 8, 2012Phase 1 study in Bioequivalence StudyNCT01595425 · 71 enrolled · Japan
- Aug 17, 2012Phase 3 study in Esophagitis, PepticNCT01669811 · 1,398 enrolled · Japan
- Dec 21, 2012Phase 3 study in Peptic Ulcer HemorrhageNCT01757275 · 239 enrolled · China
- Oct 14, 2013Phase 1 study in Stomach UlcerNCT01964131 · 34 enrolled · Japan
- May 28, 20142 phase 3 studiesNCT02157376, NCT02153398
- Dec 11, 2015Phase 3 study in Gastroesophageal RefluxNCT02670642 · 877 enrolled · Austria, France, Germany and more
- Apr 5, 2018Phase 3 study in Esophagitis, PepticNCT03553563 · 50 enrolled · Japan
- Jan 31, 2022Phase 3 study in Gastroesophageal RefluxNCT05267613 · 53 enrolled · United States, Argentina, Australia and more
TargetBeta
“Potassium-transporting ATPase inhibitor; Potassium-transporting ATPase inhibitor; Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rabeprazolerule | Eisai | phase 4 | 66 |
| Omeprazolerule | AstraZeneca | phase 4 | 56 |
| tegoprazanrule | HK inno.N | phase 4 | 48 |
| vonoprazanrule | Takeda | phase 4 | 48 |
| fexuprazanrule | Daewoong Pharmaceutical | phase 4 | 29 |
Studies
The newest 60 of 92 AstraZeneca leads. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05267613Gastroesophageal Reflux · United States, Argentina, Australia and more | 3 | Completed | Aug 10, 2026 | 53 |
| NCT03553563Esophagitis, Peptic · Japan | 3 | Completed | Dec 27, 2022 | 50 |
| NCT02670642Gastroesophageal Reflux · Austria, France, Germany and more | 3 | Completed | Nov 2002 | 877 |
| NCT02153398Stomach Ulcer · Japan | 3 | Completed | Apr 2016 | 55 |
| NCT02157376Gastrointestinal Hemorrhage · China | 3 | Completed | Feb 2016 | 343 |
| NCT01964131Stomach Ulcer · Japan | 1 | Completed | Dec 2013 | 34 |
| NCT01757275Peptic Ulcer Hemorrhage · China | 3 | Completed | Dec 2014 | 239 |
| NCT01669811Esophagitis, Peptic · Japan | 3 | Completed | May 2014 | 1,398 |
| NCT01595425Bioequivalence Study · Japan | 1 | Completed | Jun 2012 | 71 |
| NCT01494402Bioequivalence Study · Japan | 1 | Completed | Mar 2012 | 77 |
| NCT01397084Gastroesophageal Reflux | 4 | Completed | Jan 2012 | 107 |
| NCT01370538Heartburn · United States | 3 | Completed | Oct 2011 | 341 |
| NCT01370525Heartburn · United States | 3 | Completed | Oct 2011 | 340 |
| NCT01358383Arthritis, Juvenile · United States | 1 | Completed | Jun 2011 | 28 |
| NCT01249651Heartburn · China | 4 | Completed | Jun 2011 | 101 |
| NCT01210339Cardiovascular Diseases · Sweden | 1 | Completed | Aug 2011 | 58 |
| NCT01199328Peptic Ulcer · United States | 1 | Completed | Nov 2010 | 34 |
| NCT01163630Effect of Food · United States | 1 | Completed | Sep 2010 | 24 |
| NCT01159145Pharmacodynamics Study · Japan | 1 | Completed | Sep 2010 | 42 |
| NCT01119768Non-Erosive Reflux Disease · China | 4 | Completed | Jun 2011 | 305 |
| NCT01094483Platelet Inhibition · United States | 1 | Completed | May 2010 | 40 |
| NCT01069939Stomach Ulcer · Japan, Korea, Republic of, Taiwan | 3 | Completed | Nov 2011 | 427 |
| NCT01015729Peptic Ulcer · Canada | 1 | Terminated | 30 | |
| NCT00998075Peptic Ulcer · Canada | 1 | Completed | Dec 2009 | 138 |
| NCT00992381Healthy · Australia | 1 | Completed | 24 | |
| NCT00930215Healthy · Japan | 1 | Completed | 48 | |
| NCT00907400Healthy · Sweden | 1 | Completed | Sep 2009 | 48 |
| NCT00761501Healthy Volunteer · Sweden | 1 | Completed | Dec 2008 | 38 |
| NCT00734097Gastroesophageal Reflux · Argentina, Chile, Colombia and more | 4 | Completed | Oct 2008 | 314 |
| NCT00688428Ulcer | 1 | Completed | Apr 2008 | 84 |
| NCT00687245Gastroesophageal Reflux | 1 | Completed | May 2008 | 40 |
| NCT00684190Gastroesophageal Reflux · Sweden | 1 | Completed | Jun 2008 | 30 |
| NCT00676117Healthy · Japan | 1 | Completed | Jul 2008 | 30 |
| NCT00660660Gastroesophageal Reflux · United States | 4 | Completed | Jul 2008 | 276 |
| NCT00644735Heartburn | 4 | Completed | Jan 2004 | 750 |
| NCT00641602Heartburn | 4 | Completed | Aug 2003 | 1,000 |
| NCT00637988Barrett Esophagus | 4 | Completed | Jun 2003 | 32 |
| NCT00637845Heartburn | 4 | Completed | Feb 2003 | 248 |
| NCT00637559Barrett Esophagus | 4 | Completed | Apr 2003 | 50 |
| NCT00635414Gastroesophageal Reflux | 4 | Completed | Oct 2002 | 60 |
| NCT00633412Stomach Ulcer | 3 | Completed | 400 | |
| NCT00634114Esophagitis, Peptic · Japan | 3 | Completed | 540 | |
| NCT00633932Esophagitis, Peptic · Japan | 3 | Completed | 602 | |
| NCT00633672Stomach Ulcer | 3 | Completed | Oct 2003 | 400 |
| NCT00629928Stomach Ulcer | 3 | Completed | Mar 2003 | 800 |
| NCT00629564Gastroesophageal Reflux | 4 | Completed | Oct 2002 | 60 |
| NCT00629512Stomach Ulcer | 3 | Completed | Dec 2002 | 504 |
| NCT00628953Asthma | 2 | Completed | Apr 2004 | 1,400 |
| NCT00628667Chronic Posterior Laryngitis (CPL) | 4 | Completed | Mar 2003 | 120 |
| NCT00628342Gastroesophageal Reflux | 4 | Completed | Aug 2003 | 600 |
| NCT00626535Symptomatic Gastroesophageal Reflux Disease (sGERD) | 3 | Completed | Feb 2004 | 500 |
| NCT00626262Gastroesophageal Reflux | 4 | Completed | Oct 2002 | 60 |
| NCT00625495Gastroesophageal Reflux | 4 | Completed | Nov 2002 | 60 |
| NCT00625274Heartburn | 4 | Completed | Nov 2004 | 100 |
| NCT00608712Postoperative Bariatric Surgery | 4 | Completed | Aug 2006 | 140 |
| NCT00595517Stomach Ulcer · Japan | 3 | Completed | Sep 2009 | 395 |
| NCT00542789Stomach Ulcer · Japan | 3 | Completed | 343 | |
| NCT00474019Pharmacokinetics · United States, Australia, Belgium and more | 1 | Completed | 42 | |
| NCT00444275Gastroesophageal Reflux · France | 4 | Completed | Oct 2008 | 3,029 |
| NCT00441727Stomach Ulcer · United States, Argentina, Australia and more | 3 | Completed | Aug 2008 | 2,426 |
How it is read
Names in the registry
- “Esomeprazole”, 72 entries
- “esomeprazole”, 8 entries
- “PN400”, 8 entries
- “Esomeprazole (Nexium)”, 3 entries
- “HIP1601”, 3 entries
Codes read as this program: D961H, D026.
Conditions, from the studies’ own filings
- Gastroesophageal Reflux, 40 studies
- Stomach Ulcer, 13 studies
- Heartburn, 9 studies
- Esophagitis, Peptic, 6 studies
- Gastrointestinal Diseases, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.